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We studied 335682 county residents, of whom 113298 had been prescribed antihypertensive treatment (AHT), in the period
1989–2002 in North Jutland County, Denmark to examine the relation between different AHTs and the risk of renal cell carcinoma
(RCC). An internal comparison was performed among the different classes of AHT users with users of beta blockers as the reference,
in order to address potential confounding and bias. The average follow-up was 10 years (range 0–13). Use of any AHT was
associated with RCC (relative rate (RR)¼1.6, 95% confidence interval (CI) 1.3–1.9) compared with nonusers in the general
population. Specific classes of AHTs were nonsignificantly associated with RCC, but compared with users of beta blockers, the
numbers observed were close to expectation. Analyses by duration of follow-up and number of prescriptions revealed no clear
trends for any antihypertensive agent and after 5-years of follow-up, the RRs for all classes of AHT decreased. The elevated RRs for
RCC among users of AHTs compared with the general population are unlikely to be causal, but rather reflect confounding due to
failure to control for pre-existing hypertension, and protopathic bias, due to the presence of hypertension as an early sign of kidney
disease.
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Hypertension is estimated to contribute to one in eight deaths
worldwide (WHO, 2002) and up to 60% of affected individuals in
the US are on antihypertensive treatment (AHT) (Chobanian et al,
2003). Concerns have been raised that certain AHT may increase
the risk of renal cell carcinoma (RCC) whether by being directly
carcinogenic, by eliciting or accelerating other carcinogens, or by
impairing defence mechanisms (Yu et al, 1986; McLaughlin et al,
1995; Grossman et al, 2001).
Past studies have suggested an association between diuretics and
RCC, but other AHTs were not studied as extensively. Though we
have reported on use of calcium channel blockers and ACE
inhibitors in relation to cancer in general in North Jutland County,
Denmark, we did not look in any detail at RCC risk in relation to
the wide variety of specific AHTs (Olsen et al, 1997; Sorensen et al,
2000; Friis et al, 2001); these earlier studies had relatively short
follow-up periods, ending in 1993, 1995 and 1996, respectively. The
current study updates the follow-up period through 2002 and
examines the relation between the all five major classes of AHTs
(Capella, 1993), that is, diuretics, beta blockers, calcium antago-
nists, angiotensin converting enzymes (ACE) inhibitors and
angiotensin II antagonists, as well as specific classes of diuretics,
in relation to RCC.
MATERIALS AND METHODS
Study population
The study was conducted among 335682 residents of North
Jutland County, Denmark, with no prior diagnosis of any type of
cancer, between 30 and 85 years old, and resident in the county on
1 January 1989. Age was restricted to those between 30 and 85
years old because of the limited number of people outside these
ages who were first time users of AHT. Of these, 113298 had been
prescribed an AHT between the years 1989 and 2002. These data
sources have been described in previous studies in this population
(Olsen et al, 1997; Sorensen et al, 2000; Friis et al, 2001)
Exposure group
Prescriptions of AHT medications were ascertained from the
Pharmacoepidemiological Prescription Database for individuals in
the study population between the years 1989 and 2002. Along with
type of drug prescribed according to the Anatomical Therapeutical
Chemical (ATC) classification system (Capella, 1993), date of
dispensing at the pharmacy and the patient’s civil registry number
were abstracted from this database. In an attempt to address the
problem of noncompliance, we required two or more AHT
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yprescriptions recorded in the prescription database during the
study period for a person to be classified as exposed. To ensure
correct identification of exposure status for those who might have
started AHT therapy prior to 1989, 1989 data were used only to
assess exposure status, and follow-up was initiated in 1990.
AHT medications were recorded in the pharmacy database by
their ATC code, managed and developed by the World Health
Organization (WHO, 2004). In this classification system, the drugs
are divided into different groups according to the organ or system
on which they act and their chemical, pharmacological and
therapeutic properties. For this study, we identified all prescrip-
tions filled for AHT medications, including diuretics (ATC
group¼C03), beta blockers (ATC group¼C07), calcium channel
blockers (ATC group¼C02D, C08C, C08D (minus C08DA51)),
ACE inhibitors (ATC group¼C02E, C02L, C09A, C09BA) and
angiotensin II antagonists (ATC group¼C09C, C09D). In addition,
specific types of diuretics were examined. These included thiazides
(ATC group¼C03A); sulphonamides, mercurial diuretics, xanthine
derivatives and other low-ceiling diuretics except thiazides (ATC
group¼C03B); loop (or high-ceiling diuretics) (ATC group¼
C03C); potassium-sparing agents (ATC group¼C03D); and
diuretics and potassium-sparing agents in combination (ATC
group¼C03E).
Renal cell cancer (RCC)
Cases of RCC had either an ICD7 code of 180.0 (kidney cancer, not
otherwise specified) or 180.3 (renal cell cancer). ‘Kidney cancers,
not otherwise specified’, were regarded as situated in the renal
parenchyma as a previous validation study indicated that most of
these tumours are RCC (Mellemgaard et al, 1993). We excluded
cancers of the renal pelvis and ureter (ICD7¼180.1, 180.2) as their
aetiology resembles that of bladder cancer (McLaughlin and
Lipworth, 2000).
Follow-up
Follow-up began on the date of the second prescription for AHT
medication or 1 January 1990, whichever was later. Follow-up
ended at diagnosis of RCC, age 85, death, emigration from the
county, or 31 December 2002, whichever was earliest. The person-
time of the study subjects was distributed according to use of AHT
medications in exposed time (X2 prescriptions for AHT) (AHT
users) and unexposed time (one or no prescriptions for any AHT)
(nonusers).
Statistical analysis
Simple descriptive statistics, including frequencies, percentages
and means, were calculated to describe the study cohort. Log-
linear Poisson regression analysis with the logarithm of person-
years at risk as an offset variable was used to estimate the rate
ratios associated with use of each type of AHT medication. All
models were adjusted for calendar period (1990–1994 or 1995–
2002), gender and age group (30–49, 50–59, 60–69 or 70–85).
Subjects could change between categories of covariates and
specific types of AHT over time, except for the analyses of
‘exclusive users’ where subjects did not change between categories
of specific types of AHT use. In order to control for potential
unmeasured confounding or bias in risk estimates for users of
AHT medication based on comparisons with the general popula-
tion, we also performed a direct comparison between users of a
specific AHT and beta blockers. Beta-blockers’ pharmacodynamic
‘target organs’ are outside the kidney (namely heart and vessels).
These direct comparisons were restricted to ‘exclusive users’ of the
various AHT medications, including the reference category of beta
blockers. Beta blockers were chosen as the reference group because
there is no consistent evidence that use of these compounds is
associated with increased risk of cancer (Grossman et al, 2001).
Since many of these drugs could be used in combination, we also
performed analyses for ‘exclusive users’ of specific AHT medica-
tions.
Further stratified analyses on the whole study population
comparing AHT users and the general population for duration of
follow-up (1, 1–4 and 5 or more years) and number of
prescriptions (2–4, 5–9, 10þ prescriptions) were also performed.
Within each categorical level all variables were treated as time
independent. The statistical analysis was performed in SAS 8.02.
RESULTS
For the 335682 people in the study population, the average follow-
up was 10 years (range¼0–13 years). The 113298 people
prescribed two or more AHT prescriptions (exposed cohort)
accrued a total of 706428 person-years of follow-up, yielding an
average follow-up of 6 years (range¼0–13 years). Other
characteristics of AHT users are shown in Table 1. More women
(58%) than men (42%) were prescribed AHT and, as expected,
most of the prescriptions were for people over age 50 (77%) with
Table 1 Characteristics of users of antihypertensive medications, North
Jutland, Denmark, 1989–2002
Antihypertensive medication
users
a
Characteristic Number Percent
Total 113298 (100)
Men 47373 (42)
Women 65925 (58)
Age at entry
b
o50 years 25900 (23)
50–69 years 49768 (44)
X70 years 37630 (33)
Mean age at entry (range)
b 62 (30–85)
Year of entry
b
1990–1992 53139 (47)
1993–1995 20786 (18)
1996–1998 16718 (15)
1999–2002 22655 (20)
Number of prescriptions for any antihypertensive medication
2–5 21294 (19)
6–10 13688 (12)
11–20 18821 (17)
X20 59495 (53)
Type of antihypertensive medication
c
Any antihypertensive 113298 (34)
ACE inhibitor 29486 (9)
Angiotensin II antagonist 13755 (4)
Beta blocker 42866 (13)
Calcium antagonist 34816 (10)
Diuretic 83060 (25)
Low-ceiling diuretics, thiazides 45714 (14)
Sulphonamides and other low-ceiling
diuretics
4976 (1)
Loop (high-ceiling) diuretics 36197 (11)
Potassium-sparing agents 7894 (2)
Diuretics and potassium-sparing
agents in combination
15582 (5)
aTwo or more prescriptions for antihypertensive medications.
bDate of second
prescription.
cSince cohort members may use more than one antihypertensive
medication, the total number exceeds the total number of people in the cohort.
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of the second AHT prescription) of 62 years (range¼30–85
years). More than half of the cohort (53%) had received 20 or
more prescriptions for AHT. Diuretics were the most common
type of AHT medication prescribed (25%), most of which were
thiazides. Beta blockers and calcium antagonist were prescribed
for at least 10% of the population of AHT users, while fewer
prescriptions were filled for ACE inhibitors and angiotensin II
antagonists.
After controlling for age, gender and calendar period, users of
any type of AHT were 1.6 times (95% CI¼1.3–1.9) more likely to
have RCC compared with individuals in the general population
who did not use AHTs (Table 2). Use of ACE inhibitors (relative
rate (RR)¼1.9, 95% CI¼1.4–2.5), beta blockers (RR¼1.7, 95%
CI¼1.3–2.2), calcium antagonist (RR¼1.4, 95% CI¼1.0–1.8)
and diuretics (RR¼1.6, 95% CI¼1.2–2.0) were all significantly
associated with RCC. Furthermore, the risk for RCC among each
specific class of diuretics was elevated, with a significant
association for loop diuretics (RR¼2.0, 95% CI¼1.5–2.7), and
potassium-sparing agents (RR¼2.2, 95% CI¼1.3–3.8).
Next, we examined the relation between exclusive use of a
specific class of AHT and RCC risk. Most of the relative risks were
attenuated but slight to moderately elevated risks were still
present. However, there were no significant differences in RCC
risk among different classes of drugs when exclusive users of
specific AHT medications were compared with beta blocker users,
with risks of 1.2 (95% CI¼0.4–3.3) for ACE inhibitors, 1.0 (95%
CI¼0.1–7.5) for angiotensin II antagonist, 0.9 (95% CI¼0.4–1.9)
for calcium antagonist, and 0.9 (95% CI¼0.5–1.6) for diuretics.
Table 3 presents the association between the various classes of
AHT and RCC by duration of follow-up using the general
population as the comparison group. Overall, the relation between
Table 2 Relative rates (RR) and 95% confidence intervals (CI) for the relation between antihypertensive medication use and renal cell cancer (RCC) for
individuals who ever used a specific class of antihypertensive medication and for those who exclusively used a specific class of antihypertensive medication
compared to the general population or to people who use beta blockers in North Jutland County, 1989–2002
Ever used antihypertensive medication Exclusive use of specific class of antihypertensive medication
General population General population Beta blockers
RCC
cases
Person-
years RR
a (95% CI)
RCC
cases
Person-
years RR
a (95% CI) RR
a (95% CI)
Any antihypertensive 191 706428 1.6 (1.3–1.9)
ACE inhibitor 52 147096 1.9 (1.4–2.5) 5 18545 1.8 (0.8–4.5) 1.2 (0.4–3.3)
Angiotensin II antagonist 9 43456 1.1 (0.6–2.2) 1 4958 1.4 (0.2–10.2) 1.0 (0.1–7.5)
Beta blocker 72 245971 1.7 (1.3–2.2) 15 73179 1.6 (0.9–2.7) 1.0 (Referent)
Calcium antagonist 59 195715 1.4 (1.0–1.8) 9 34915 1.3 (0.6–2.5) 0.9 (0.4–1.9)
Diuretic 138 489470 1.6 (1.2–2.0) 55 236455 1.4 (1.0–1.9) 0.9 (0.5–1.6)
Thiazides 62 248890 1.3 (0.9–1.7) 14 77421 1.0 (0.6–1.7) 0.7 (0.3–1.5)
Sulphonamides and other
low-ceiling diuretics
9 35407 1.4 (0.7–2.7) 3 11482 1.6 (0.5–5.0) 1.1 (0.3–3.7)
Loop (high-ceiling) diuretics 70 168311 2.0 (1.5–2.7) 13 41785 1.6 (0.9–2.8) 1.1 (0.5–2.4)
Potassium-sparing agents 15 30550 2.2 (1.3–3.8) 1 1164 5.0 (0.7–36.0) 3.3 (0.4–25.1)
Diuretics and potassium-
sparing agents in combination
25 111436 1.3 (0.8–1.9) 4 40316 0.6 (0.2–1.6) 0.4 (0.1–1.2)
aAdjusted for age, gender and calendar period.
Table 3 Relative rates (RR) and 95% confidence intervals (CI) for the relation between antihypertensive medication use and renal cell cancer (RCC) by
years of follow-up in North Jutland County, 1989–2002
o1 year 1–4 years 5+ years
Years of follow-up
Number
RCC
Person-
years RR
a 95% CI
Number
RCC
Person-
years RR
a 95% CI
Number
RCC
Person-
years RR
a 95% CI
Any hypertensive 33 95484 2.0 (1.4–2.9) 89 323680 1.6 (1.2–2.0) 69 287264 1.4 (1.0–1.8)
ACE inhibitor 12 26154 2.3 (1.3–4.2) 30 71859 2.2 (1.5–3.2) 10 49084 1.1 (0.6–2.1)
Angiotensin II antagonist 4 12072 1.9 (0.7–5.0) 5 27022 1.0 (0.4–2.5) 0 4362 0.0 —
Beta blocker 14 37211 2.2 (1.3–3.8) 34 114335 1.7 (1.2–2.5) 24 94425 1.4 (0.9–2.1)
Calcium antagonist 9 30749 1.4 (0.7–2.7) 31 96677 1.5 (1.0–2.2) 19 68288 1.2 (0.7–2.0)
Diuretic 22 71157 1.7 (1.1–2.6) 70 227812 1.7 (1.3–2.2) 46 190501 1.4 (1.0–1.9)
Thiazides 7 40613 0.9 (0.4–1.9) 36 120761 1.5 (1.1–2.2) 19 87516 1.1 (0.7–1.8)
Sulphonamides and
other low-ceiling diuretics
1 4257 1.3 (0.2–9.2) 3 15006 1.1 (0.3–3.4) 5 16144 1.7 (0.7–4.1)
Loop (high-ceiling)
diuretics
17 30512 2.5 (1.5–4.1) 37 84227 2.1 (1.5–3.0) 16 53572 1.6 (0.9–2.7)
Potassium-sparing agents 9 6338 6.0 (3.1–11.8) 5 14607 1.5 (0.6–3.7) 1 9606 0.5 (0.1–3.6)
Diuretics and potassium-
sparing agents in
combination
5 13457 2.1 (0.9–5.1) 12 48587 1.4 (0.8–2.5) 8 49393 0.9 (0.4–1.8)
aAll analyses adjusted for age, gender and calendar period.
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CI¼1.4–2.9; RR for 1–4 years¼1.6, 95% CI¼1.2–2.0; RR for 5
and more years¼1.4, 95% CI¼1.0–1.8). A similar pattern of
decreasing risk with increasing duration of follow-up was found
for ACE inhibitors, angiotensin II antagonist, beta blockers and
calcium antagonists. Overall, for the various classes of diuretics, no
trends of increasing or decreasing risks were apparent over time.
None of the specific types of AHT drugs was significantly
associated with RCC after 5 or more years of follow-up.
Overall, no increasing or decreasing trend in RCC risk with
increasing number of prescriptions for AHT medications was
apparent (Table 4). Similar patterns were seen for the specific
classes of AHT and diuretics in particular. RRs were remarkably
similar for individuals with 10 or more prescriptions for virtually
all classes of AHT medications with point estimates ranging
between 1.4 and 1.8, and for the various types of diuretics, with
point estimates ranging from 1.0 to 1.7.
DISCUSSION
Although, there was an increased risk for RCC among users of
AHT medications compared with nonusers in the general
population, risk for exclusive use of any class of AHT medication
was not significantly elevated compared with either the general
population or with users of beta blockers. In fact, in comparison
with beta blockers, the risk estimates were close to unity for all
major groups of AHT medications. Neither duration of follow-up
nor number of prescriptions was associated with RCC for any of
the classes of AHT medications.
It is known that early-stage prediagnostic renal tumours may
themselves lead to increases in blood pressure and the observed
association between AHT medication and RCC is likely to reflect to
some extent this type of protopathic bias. Our data lend some
support for this view. After 5-years of follow-up, the risk ratios for
all classes of AHT medications decreased, indicating that the onset
of hypertension as an early sign of kidney cancers rather than the
treatment per se is related to RCC.
Numerous observational studies have suggested that elevated
risk ratios, may, in fact, reflect a relation between pre-existing high
blood pressure and RCC. Thus, failure to adjust for confounding
by pre-existing hypertension in our study may have generated
inflated risk estimates. When adjustment for high blood pressure
is performed, it appears to eliminate the excess risk associated with
diuretic use (McLaughlin et al, 1995). We examined the specific
classes of diuretics and found similar risks across all groups. As
the five classes of diuretics have different modes of action, it is
reasonable to assume that if these medications were related to
RCC, risk would differ across the specific classes of diuretics. This
was not the case in our study, as the risk for RCC was similarly
elevated for all classes of diuretics. When compared with beta
blockers, the risk for RCC among each group of diuretics except
potassium-sparing agents was near unity and no trend in risk was
apparent with increasing duration of follow-up or number of
prescriptions. Only one case of RCC was diagnosed among users of
potassium-sparing agents. Based on past studies in this population
and others, it is unlikely that calcium antagonists or beta blockers,
or ACE inhibitors are associated with cancer (McLaughlin et al,
1995; Olsen et al, 1997; McLaughlin and Lipworth, 2000; Sorensen
et al, 2000; Friis et al, 2001; Grossman et al, 2001). To our
knowledge this is the first study to examine the relation between
angiotensin II antagonists and RCC.
The strengths of the study include the large size with over 3
million person-years of follow up and 471 cases of RCC resulting in
an improved statistical precision compared with earlier studies,
and complete follow-up of the cohort through use of the unique
CPR number with computerised linkage to nationwide Danish
registers. A further strength is that beta-blockers are available in
Denmark only by prescription, and we have identified practically
all users in the study population. The limitations include the fact
that the prescription database was only established in 1989 so
earlier drug history is unknown. Information on well known or
suspected risk factors for RCC, such as cigarette smoking, obesity
and possibly hypertension was not available. Several large-scale
population-based case–control and cohort studies which adjusted
for use of diuretics and other AHT have reported elevated relative
risks for RCC associated with hypertension, independent of use of
AHT (McLaughlin et al, 1995; Yuan et al, 1998; Chow et al, 2000;
McLaughlin and Lipworth, 2000). In contrast, adjustment for high
blood pressure appears to eliminate any excess risk for RCC
Table 4 Relative rates (RR) and 95% confidence intervals (CI) for the relation between antihypertensive medication use and renal cell cancer (RCC) by
number of prescriptions in North Jutland County, 1989–2002
2–4 prescriptions 5–9 prescriptions 10+ prescriptions
Years of follow-up
Number
RCC
Person-
years RR
a 95% CI
Number
RCC
Person-
years RR
a 95% CI
Number
RCC
Person-
years RR
a 95% CI
Any hypertensive 34 144503 1.6 (1.1–2.4) 28 121168 1.4 (0.9–2.1) 129 440757 1.6 (1.3–2.0)
ACE inhibitor 9 33171 1.5 (0.8–2.9) 14 31214 2.4 (1.4–4.1) 29 82712 1.8 (1.2–2.7)
Angiotensin II antagonist 4 10604 2.1 (0.8–5.7) 2 11779 0.9 (0.2–3.8) 3 21074 0.8 (0.2–2.4)
Beta blocker 25 66398 2.4 (1.6–3.7) 10 55998 1.0 (0.5–1.9) 37 123576 1.6 (1.1–2.3)
Calcium antagonist 10 41033 1.2 (0.6–2.3) 11 39441 1.3 (0.7–2.4) 38 115241 1.4 (1.0–2.0)
Diuretic 28 135964 1.3 (0.9–1.9) 30 108244 1.5 (1.0–2.3) 80 245261 1.7 (1.3–2.2)
Low-ceiling diuretics,
thiazides
14 86346 0.9 (0.5–1.6) 17 65314 1.3 (0.8–2.2) 31 97230 1.5 (1.0–2.2)
Sulphonamides and
other low-ceiling
diuretics
5 12202 2.5 (1.0–6.1) 1 8788 0.6 (0.1–4.4) 3 14418 1.0 (0.3–3.3)
Loop (high-ceiling)
diuretics
18 52196 1.9 (1.1–3.0) 23 36850 3.0 (1.9–4.6) 29 79265 1.7 (1.1–2.5)
Potassium-sparing
agents
8 9068 4.0 (2.0–8.1) 2 7376 1.2 (0.3–4.8) 5 14106 1.6 (0.7–4.0)
Diuretics and
potassium-sparing
agents in combination
9 34157 1.6 (0.8–3.1) 6 24606 1.3 (0.6–3.0) 10 52674 1.0 (0.5–1.9)
aAll analyses adjusted for age, gender and calendar period.
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Shapiro et al, 1999; McLaughlin and Lipworth, 2000). In an attempt
to control for potential confounding variables, we compared beta
blockers and other medications and found that all of the risk
estimates were close to expectation.
Diabetes has been suggested as a risk factor for RCC, but the
evidence is not consistent (Wideroff et al, 1997; Coughlin et al,
2004). Exclusion of diabetics did not materially change the risk
estimates (data not shown), suggesting that diabetes does not play
a major role in the aetiology of RCC in this cohort.
In summary, none of the AHTs studied was consistently
associated with risk of RCC, and analyses by duration of follow-
up and number of prescriptions indicated that it is unlikely that
any of these medications plays an important role in the aetiology
of RCC. Elevated RRs for RCC among of AHT users compared with
the general population are unlikely to be causal, but rather reflect
confounding, from failure to control for pre-existing hypertension,
which appears to be an independent risk factor for RCC, from
hypertension as an early sign of kidney cancer and possibly from
increased medical surveillance.
ACKNOWLEDGEMENTS
This study was funded by the International Epidemiology Institute,
Rockville, Maryland, USA, the Ingeborg and Leo Dannins Founda-
tion for Scientific Research, and the Western Danish Research
Forum for Health Sciences (Vestdansk Forskningsforum).
REFERENCES
Capella D (1993) Descriptive tools and analysis. In Drug Utilization Studies:
Methods and Uses WHO Regional Publications, European Series No. 45,
Dukes MNG (ed) pp 55–78. Geneva: World Health Organization
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL,
Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, National
Heart, Lung, and Blood Institute Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure; National High Blood Pressure Education Program Coordinat-
ing Committee (2003) The seventh report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC 7 Report. JAMA 289(19): 2560–2572
Chow WH, Gridley G, Fraumeni Jr JR, Jarvholm B (2000) Obesity,
hypertension and the risk of kidney cancer in men. N Engl J Med 343:
1305–1311
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes
mellitus as a predictor of cancer mortality in a large cohort of US adults.
Am J Epidemiol 159: 1160–1167
Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ,
Olsen JH (2001) Angiotensin-converting enzyme inhibitors and the risk of
cancer: a population-based cohort study in Denmark. Cancer 92: 2462–2470
Grossman E, Messerli FH, Goldbourt U (2001) Antihypertensive therapy
and the risk of malignancies. Eur Heart J 22: 1343–1352
McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M,
Lindblad P, Schlehofer B, Pommer W, Niwa S, Adami HO (1995)
International renal-cell cancer study. VIII. Role of diuretics, other anti-
hypertensive medications and hypertension. Int J Cancer 63: 216–221
McLaughlin JK, Lipworth L (2000) Epidemiologic aspects of renal cell
cancer. Semin Oncol 27: 115–123
Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH (1993)
Trends in the incidence of cancer of the kidney, pelvis, ureter and
bladder in Denmark 1943–88. Scand J Urol Nephrol 27: 327–332
Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL,
Andersen M, Fraumeni Jr JF, Olsen J (1997) Cancer risk in users of
calcium channel blockers. Hypertension 29: 1091–1094
Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE
(1999) Hypertension, antihypertensive medication use, and risk of renal
cell carcinoma. Am J Epidemiol 149: 521–530
Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH,
McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of
calcium channel blockers. A cohort study. Cancer 89: 165–170
The WHO Collaborating Centre for Drug Statistics Methodology [Internet]
(2004). Oslo, Norway: Norwegian Institute of Public Health, [updated
2004 Jan 5; cited 2004 Jul 27]. Available from: http://www.whocc.no/
atcddd/
The World Health Report (2002) Reducing Risks Promoting Health Life.
Geneva, Switzerland: World Health Organization, p 58
Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-
Johnsen K, Olsen JH (1997) Cancer incidence in a population-based
cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl
Cancer Inst 89: 1360–1365
Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE (1986) Cigarette
smoking, obesity, diuretic use, and coffee consumption as risk factors for
renal cell carcinoma. J Natl Cancer Inst 77: 351–356
Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC (1998)
Hypertension, obesity and their medications in relation to renal cell
carcinoma. Br J Cancer 77: 1508–1513
Antihypertensive treatments and risk of renal cell cancer
JP Fryzek et al
1306
British Journal of Cancer (2005) 92(7), 1302–1306 & 2005 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y